Publications
CAR T Cells
G-Rex®100M, G-Rex®100M-CS
Publication Date: November 3, 2026
Splitting CAR-T manufacturing across separate closed unit operations, instead of consolidating it into one automated instrument, can match an established open process at lower cost. Caring Cross paired the Cytiva Sepax C-Pro — used for T-cell isolation and later for harvest and wash — with SMART G-Rex®100M-CS bioreactors, keeping the fluid path sealed throughout. Two head-to-head runs split one donor between the closed route and a validated open G-Rex®100M benchmark. Day 7 products cleared every release specification in both arms, with viability above 97% and T-cell purity above 96%; in the dose-matched run, vector copy number differed by less than 3%, and closed enrichment recovered abou…
Publications
TIL Cells
G-Rex®100M
Publication Date: November 3, 2026
Frequency readings taken through the vessel wall can say when a tumor-infiltrating lymphocyte culture is ready to harvest, without opening it. Both expansion phases of the CTMC platform were followed. First-phase cultures were started in SMART G-Rex®100M-TF from one stage IV melanoma using 5, 10 or 30 tumor fragments, and the Rapid Expansion Protocol was tracked in G-Rex®100M across five lines, with counts extrapolated to G-Rex®500M. In the first phase a reading of 142 ± 0.5 MHz marked cultures that would give 300 to 500 × 10⁶ cells on the same day, a call glucose could not make. In the Rapid Expansion Protocol, 141 ± 0.5 MHz flagged lines a day before plateau, pointing to harvest on Day…
Publications
CAR T Cells
G-Rex®100M, G-Rex®6M – 5cm² Well Plate
Publication Date: November 3, 2026
Non-invasive sensor readings can follow CAR-T growth inside a closed G-Rex® vessel closely enough to inform harvest timing. Cultures were started at CTMC from two healthy donors and from two patients with tumors, each under two activation methods, for six cultures in all; they grew in SMART G-Rex®100M bioreactors, with G-Rex®6M wells sampled in parallel as references and glucose measured daily from Day 3. The SMART Growth Index climbed through expansion and flattened once growth slowed, separating lag, log, transitional and plateau phases more sharply than glucose did, and it registered the delayed expansion of the second activation method. Readings near 6 to 8 matched the intended harves…
Publications
Other
Publication Date: November 2, 2026
FDA's final guidance on potency assurance for cellular and gene therapy products, issued in November 2026, asks manufacturers to assure potency through a science- and risk-based strategy rather than through release testing alone. It supersedes the January 2011 guidance on potency tests. The strategy combines manufacturing process design, process and material controls, in-process testing and lot release assays, grounded in quality risk management across the product lifecycle. For most products, lot release should feature one or more bioassays suited to the development phase. Potency release assays should be qualified no later than the start of trials meant to provide substantial evidence o…
Publications
CAR T Cells
G-Rex®100M-CS, G-Rex®6 Well Plate, G-Rex®6M Well Plate
Publication Date: July 29, 2026
A closed, gas-permeable bioreactor workflow can combine T-cell enrichment, activation, static retroviral transduction and expansion in a single vessel for GD2 CAR T-cell manufacturing. RetroNectin-coated G-Rex® surfaces supported transduction without spinoculation, and a single media exchange between 24 and 96 hours after transduction did not significantly change yield or viability. In three healthy-donor runs in G-Rex® 100M-CS vessels, in-vessel CD4/CD8 magnetic enrichment recovered 61.6% of target cells at 87.2% purity. Seven-day cultures reached 62.3% transduction efficiency and 26.8-fold expansion with viability above 94%, performing comparably to historical CliniMACS Prodigy products…
Publications
CAR T Cells
G-Rex®24 Well Plate
Publication Date: July 20, 2026
Base editors can be repurposed for non-viral transgene knock-in while also performing multiplex gene knockouts with a single enzyme, an approach called BEKI. Paired nicks from the nickase domain, with PAM-out guides placed roughly 30 to 175 bp apart, drove CAR insertion at four T cell loci. Adding DNA-PK and Polθ inhibitors raised adenine base editor knock-in efficiency to as high as 40.2% at CD3ζ. In a comparison across TRAC, RASA2 and FKBP12, Cas9-edited cells showed balanced translocations at frequencies up to 4%, whereas none were detected with BEKI. BEKI combined CAR knock-in with up to 10 additional knockouts, and expansion in G-Rex® bioreactors for 7 days gave a mean 9-fold CAR+ T…
Publications
CAR T Cells
G-Rex®10M
Publication Date: July 15, 2026
A 3-day process can generate CD19-CD20-CD22 trispecific CAR T-cells directly from whole blood, giving a product with high viability and cytotoxicity comparable to a 7-day culture. T-cells were negatively selected with a T-isopure antibody cocktail and automated density gradient separation, raising CD3+ cells from 18.9% to 88.5% of CD45+ cells with 40.6% mean recovery. After activation, lentiviral transduction and culture in G-Rex® 10 M vessels, day 3 products showed viability of 96.6%, 47.51% transduction by day 3 and VCN of 2.02. Day 3 and day 7 products killed NALM6 cells similarly at 5:1, 2:1 and 1:1 effector-to-target ratios, while day 3 gene expression was more memory-like and day 7…
Publications
Other
Publication Date: July 13, 2026
FDA has proposed amending its drug establishment registration rules so that a distributed manufacturing establishment, which makes the same drug at several physical sites under one quality unit, could register as a single establishment rather than separately registering each site. The proposal also aligns rules for foreign establishments with the PREVENT Pandemics Act, requiring registration and listing even when a drug, such as an active pharmaceutical ingredient, is further processed at another foreign site before import. Mobile units would require at least 30 days' advance notice for moves within or to the United States and 120 days for moves within or to a foreign country. FDA estimat…
Publications
CAR T Cells
Publication Date: July 1, 2026
A-Cell is an industry consensus case study that shows how Quality by Design principles can be applied to chemistry, manufacturing and controls programs for cell-based therapies, using a hypothetical lentiviral vector-modified CAR-T product. Created by the Alliance for Regenerative Medicine, it follows earlier A-Mab and A-Gene efforts and draws on contributions from more than 50 industry experts at over 30 developers and service or technology providers. The document spans 11 chapters, from regulatory considerations and risk assessment to ancillary materials, vector manufacturing, analytics, control strategy and facility design. Its data are non-proprietary and intended for illustrative pur…
Publications
CTL Cells
G-Rex®10, G-Rex®100
Publication Date: June 30, 2026
Intravenous autologous T cells targeting WT1, PRAME and survivin were feasible and generally well tolerated in mainly pediatric patients with high-risk central nervous system tumors in the ReMIND phase 1 trial. Of 48 patients who underwent blood procurement, 41 had products manufactured, and 33 were infused across three arms. Dose level 3, 8 × 10^7 cells per m2 per dose, was the model-estimated maximum tolerated dose; 88% of adverse events were low grade, and one grade 5 event in a patient with diffuse intrinsic pontine glioma was a dose-limiting toxicity. Median overall survival in the DIPG arm was 13.7 months from diagnosis. In relapsed arms, three patients were alive without disease at…
Scientific Posters
CAR T Cells
Publication Date: June 3, 2026
In an integrated allogeneic anti-CD19 TCRαβ-KO CAR-T platform, expanding edited cells in G-Rex® bioreactors gave about 22-fold more viable cells than Prodigy expansion under identical biological conditions. In the CERTERA-01 production, fold expansion at day 7 was 27.6× in G-Rex® versus 1.2× in Prodigy, with 2.8×10⁹ versus 1.25×10⁸ total viable cells. Across four healthy-donor runs, editing at day 7 was about 87 to 95%, residual TCRαβ⁺ cells after depletion were 0.7% or less, and CAR⁺ cells in the final product were 41%, 39%, 3% and 66%; the 3% run had a documented process deviation. Depleted product kept cytolytic activity against CD19⁺ Namalwa cells and a memory-rich phenotype (mean abo…
Publications
T-Cells
G-Rex®100M, G-Rex®100M-CS
Publication Date: June 1, 2026
The Atract Kit T-cell activation reagent performed equivalently when the workflow moved from an open to a closed G-Rex® system. PBMCs from three healthy donors were activated and expanded for 9 days in G-Rex® 100M vessels, seeded with 50 × 10^6 cells and 160 mg of Atract Kit. Both setups produced more than 3 × 10^9 cells, with no significant difference between them. Viability stayed above 80%, and the CD4/CD8 ratio was similar, with about 62% CD8 and 38% CD4 cells. Exhaustion markers PD-1, TIM-3 and LAG-3 remained low in the closed system, and CD19-positive cells stayed below 0.5% in both conditions. The closed format used a pre-production prototype of the Atract Kit.
No manuscripts match your filters.